Regenxbio (RGNX) Reports Q4 Loss, Lags Revenue Estimates

Stock Information for Sutro Biopharma Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Sutro Biopharma Inc.

REGENXBIO Announces Strategic Royalty Monetization Agreement for Up to $250 Million
FDA Accepts Biologics License Application for Mucopolysaccharidosis II Treatment
REGENXBIO Announces FDA Acceptance and Priority Review of the BLA for RGX-121 for MPS II
REGENXBIO Reports First Quarter 2025 Financial Results and Recent Operational Highlights
REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 28th Annual Meeting
REGENXBIO to Host Conference Call on May 12 to Discuss First Quarter 2025 Financial Results and Recent Operational Highlights
REGENXBIO REPORTS POSITIVE BIOMARKER DATA FROM AFFINITY DUCHENNE® TRIAL OF RGX-202 GENE THERAPY
REGENXBIO Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Operational Updates

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.